why choose us

First received: December 25, 2022

Clinical Trial: Efficacy and Safety of LYB001 as Booster Vaccination in Adults 18 Years of Age or Older

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: COVID-19

Study Type: Interventional


Official Title: A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in

Brief Summary: This is an international multicenter clinical trial, which is planned to be conducted in several research centers in China and Pakistan. A randomized, double-blind, placebo-controlled design will be conducted to evaluate the efficacy, safety of LYB001 against COVID-19 as a booster dose in China.

Read more